Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab-Reference-Cited by-同舟云学术

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab

Published:2021-10-01 Issue:10 Volume:181 Page:1278
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Crosson Francis J.¹,Covinsky Kenneth²³,Redberg Rita F.²⁴

Affiliation:

1. Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California

2. University of California San Francisco School of Medicine

3. Associate Editor, JAMA Internal Medicine

4. Editor, JAMA Internal Medicine

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2782118/jamainternal_crosson_2021_vp_210012_1632955141.30125.pdf

Reference10 articles.

1. Do subtle cognitive deficits precede amyloid accumulation? cart before the horse.;Snitz;Neurology,2020

2. History and progress of hypotheses and clinical trials for Alzheimer’s disease;Liu;Signal Transduct Target Ther,2019

3. Effect of collaborative dementia care via telephone and internet on quality of life, caregiver well-being, and health care use: the Care Ecosystem randomized clinical trial.;Possin;JAMA Intern Med,2019

4. US Food and Drug Administration. FDA’s decision to approve a new treatment for Alzheimer’s disease. June 7, 2021. Accessed June 17, 2021. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease

5. Belluck? P, Robbins? R. Three FDA advisers resign over agency’s approval of Alzheimer’s drug. New York Times. June 10, 2021. Accessed June 17, 2021. https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graves disease is associated with increased risk of clinical Alzheimer’s disease: evidence from the Medicare system;Clinical Diabetes and Endocrinology;2024-02-05

2. Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues;Expert Review of Neurotherapeutics;2023-11-24

3. Graves Disease is Associated with Increased Risk of Clinical Alzheimer’s Disease: Evidence from the Medicare System;2023-10-12

4. Statutory Authority for Medicare Coverage Decisions—CMS Is an Independent Federal Agency;JAMA Internal Medicine;2023-09-01

5. Enduring Change Happens One Step at a Time—My Time as Editor of JAMA Internal Medicine;JAMA Internal Medicine;2023-08-01